BMY vs NVCR: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of September 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. BMY and NVCR share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined BMY and NVCR exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Bristol Myers Squibb is one of the largest global biopharmaceutical companies, developing and selling prescription medicines across oncology, hematology, immunology, cardiovascular, and neuroscience. It makes money primarily by selling patented branded drugs, with a portfolio that has historically leaned on blockbuster franchises such as the blood thinner Eliquis (co-marketed with Pfizer), the cancer immunotherapy Opdivo, and the multiple myeloma drug Revlimid. The company is navigating a major patent cliff as several legacy products lose exclusivity, and it is rebuilding growth through a newer portfolio that includes drugs like Reblozyl, Opdualag, Camzyos, Sotyktu, and the schizophrenia treatment Cobenfy (acquired through Karuna). Bristol Myers grows both organically through its research pipeline and through large acquisitions (Celgene, MyoKardia, Karuna, Mirati). It is headquartered in New York and operates worldwide.

Full BMY guide

NovoCure Ltd. (Nasdaq: NVCR) is an oncology medical device company built around Tumor Treating Fields (TTFields), a therapy that delivers low-intensity alternating electric fields through wearable arrays to disrupt cancer cell division. Its FDA-approved Optune platform spans Optune Gio for glioblastoma, Optune Lua for metastatic non-small cell lung cancer and malignant pleural mesothelioma, and Optune Pax, approved in February 2026 for locally advanced pancreatic cancer. The company reported full-year 2025 net revenue of about $655 million (up ~8%) with roughly 4,620 active patients on therapy at year-end.

Full NVCR guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• BMY drivers: New product portfolio ramp; Oncology and immunology depth.
• NVCR drivers: New-indication launches (Optune Pax and Lua); International expansion and reimbursement wins.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The central risk is the patent cliff: Eliquis, Opdivo, and other large products face loss of exclusivity, and generic or biosimilar competition can erode revenue quickly. For NVCR, novoCure remains GAAP unprofitable and depends on new launches converting into durable revenue, which is not guaranteed.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick BMY if you believe its drivers more; NVCR if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the BMY and NVCR guides.

BMY. Bristol Myers tends to trade at a low forward earnings multiple relative to large-cap pharma peers, reflecting market skepticism about its ability to replace patent-cliff revenue. The high dividend yield and strong free cash flow are the bull-case anchors, while the depressed valuation reflects the bear case that legacy declines outrun newer products.

NVCR. NovoCure trades as a mid-single-digit-growth medical device company that is still not GAAP profitable, so it is valued more on revenue and future-indication optionality than on earnings. The recent quarterly loss was amplified by a roughly $43 million one-time share-based-comp charge linked to the Optune Pax approval. Over $400 million in cash against modest debt gives operating runway while the newer launches scale.

Headline figures (approximate, early 2026): BMY shows revenue (ttm) ~$48 billion, operating margin ~20% (varies with acquisition charges), net income (ttm) volatile, pressured by large acquisition write-offs, dividend yield ~4-5%; NVCR shows revenue (fy2025) ~$655M, revenue (q1 2026) ~$174M (up ~12% YoY), 2026 revenue guidance ~$690M to $710M, gross margin (q1 2026) ~78%.

BMY and NVCR are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined BMY and NVCR exposure against your real portfolio. It is not an investment adviser.